| Consegna Pharma Development Pipeline | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| INDICATION | PROGRAM | API | DURATION | MARKET | IN SILICO | IN VITRO | IN VIVO POC | cGMP MFG | CLINICAL PATHWAY |
| Psychiatry | CP901 | Generic Risperdal®Consta® | 14-day | $1.4B | ✔ | ✔ | ✔ | ＊ | ANDA |
| CP106 | Risperidone | 60-day | $1.4B | ✔ | ＊ | 505(b)(2) | |||
| CP103 | Quetiapine | 28-day | $2.5B | ✔ | ✔ | ＊ | 505(b)(2) | ||
| CP110 | PROPRIETARY | 28-day | ✔ | ✔ | 505(b)(2) | ||||
| CP113 | PROPRIETARY | 28-day | $2.4B | ✔ | 505(b)(2) | ||||
| CP114 | PROPRIETARY | 28-day | $1.3B | ✔ | 505(b)(2) | ||||
| CP116 | Glatiramer | 14-day | $1.0B | ✔ | 505(b)(2) | ||||
| Oncology | CP902 | Generic Sandostatin LAR® | 28-day | $1.6B | ✔ | ✔ | ANDA | ||
| CP904 | Generic Lupron Depot® | 28-day | $1.7 | ✔ | ✔ | ＊ | ANDA | ||
| CP107 | Octreotide | 90-day | $1.5B | ✔ | ✔ | 505(b)(2) | |||
| Medical Countermeasures |
CP205 | Butyrylcholinesterase | 21-day | $2.6B | ✔ | ✔ | ✔ | ✔ | 505(b)(2) |
| CP215 | Acute Radiation Syndrome | 7-day | $150M | ✔ | 505(b)(2) | ||||
| Infectious Disease |
CP109 | Antituberculosis Combo | 60-day | $600M | ✔ | 505(b)(2) | |||
| CP112 | HIV PrEP | 28-day | $2.0B | ✔ | 505(b)(2) | ||||
| Endocrinology | CP903 | Generic Bydureon® | 7-day | $600M | ✔ | ✔ | ANDA | ||
| CP108 | Exenatide | 14-day | $600M | ✔ | ✔ | 505(b)(2) | |||
| Opioid Abuse | CP216 | Naloxone | 24 hr | $200M | ✔ | 505(b)(2) | |||
* - In process
Products under patent are not for ultimate sale in countries where relevant patents have not expired.